TScan Therapeutics

TScan identifies cancer-targeting proteins to develop TCR cell therapies that engineer T cells to mount immune responses against various tumor types.
Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2021
Stage of Initial Investment
Series C
Initial Investment Year
2021